These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46 related articles for article (PubMed ID: 25468285)
21. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942 [TBL] [Abstract][Full Text] [Related]
23. Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer. Jin HJ; Jung S; DebRoy AR; Davuluri RV Oncotarget; 2016 Aug; 7(34):54616-54626. PubMed ID: 27409348 [TBL] [Abstract][Full Text] [Related]
24. A genome-wide assessment of variability in human serum metabolism. Hong MG; Karlsson R; Magnusson PK; Lewis MR; Isaacs W; Zheng LS; Xu J; Grönberg H; Ingelsson E; Pawitan Y; Broeckling C; Prenni JE; Wiklund F; Prince JA Hum Mutat; 2013 Mar; 34(3):515-24. PubMed ID: 23281178 [TBL] [Abstract][Full Text] [Related]
25. Prostate cancer: Clinical hallmarks in whole cancer genomes. Imielinski M; Rubin MA Nat Rev Clin Oncol; 2017 May; 14(5):265-266. PubMed ID: 28374788 [No Abstract] [Full Text] [Related]
26. Highlights from the prostate cancer genome report. Tan SH; Petrovics G; Srivastava S Asian J Androl; 2011 Sep; 13(5):659-60. PubMed ID: 21666698 [No Abstract] [Full Text] [Related]
27. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Gu L; Frommel SC; Oakes CC; Simon R; Grupp K; Gerig CY; Bär D; Robinson MD; Baer C; Weiss M; Gu Z; Schapira M; Kuner R; Sültmann H; Provenzano M; ; Yaspo ML; Brors B; Korbel J; Schlomm T; Sauter G; Eils R; Plass C; Santoro R Nat Genet; 2015 Jan; 47(1):22-30. PubMed ID: 25485837 [TBL] [Abstract][Full Text] [Related]
28. Genetics of prostate cancer risk. Pomerantz MM; Freedman ML Mt Sinai J Med; 2010; 77(6):643-54. PubMed ID: 21105126 [TBL] [Abstract][Full Text] [Related]
30. A comprehensive analysis of genome-wide association studies to identify prostate cancer susceptibility loci for the Romanian population. Rădăvoi GD; Pricop C; Jinga V; Mateş D; Rădoi VE; Jinga M; Ursu RI; Bratu OG; Mischianu DL; Iordache P Rom J Morphol Embryol; 2016; 57(2):467-75. PubMed ID: 27516020 [TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of genome-wide and replication association studies on prostate cancer. Liu H; Wang B; Han C Prostate; 2011 Feb; 71(2):209-24. PubMed ID: 20690139 [TBL] [Abstract][Full Text] [Related]
32. [Genome-wide association study(GWAS) and genetic risk of prostate cancer]. Nakagawa H; Akamatsu S; Takata R Nihon Rinsho; 2016 Jan; 74(1):34-9. PubMed ID: 26793876 [TBL] [Abstract][Full Text] [Related]
33. Clinical uncertainty of prostate cancer genetic risk panels. Pomerantz M; Freedman ML Sci Transl Med; 2013 Apr; 5(182):182ed6. PubMed ID: 23616119 [No Abstract] [Full Text] [Related]